Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bavituximab Plus Pembrolizumab in Advanced Gastric or Gastroesophageal Cancer
NCT04099641Phase 2Completed
- Sponsor
- OncXerna Therapeutics
- Start
- Sep 2019
- Primary completion
- Dec 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of bavituximab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by OncXerna Therapeutics. Started Sep 2019; status: completed.
02
Drugs
bavituximab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04099641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04099641.